Opens Facility to Support European Partnerships
ALAMEDA, Calif., and PARIS, March 6 /PRNewswire/ -- Singulex Inc. announced today a collaboration with Novartis Pharma AG to give Novartis access to Singulex's advanced biomarker detection technology through an Erenna(TM) Technology Access Program (ETAP). Terms of the collaboration were not disclosed. In addition, the company announced the opening of a facility in Paris, France to support the needs of Singulex's collaborators in Europe.
"We have gained tremendous traction with potential pharmaceutical partners in the last year," said Philippe Goix, Ph.D., president and CEO of Singulex. "Establishing this relationship with Novartis further validates the power of our technology in therapeutic efficacy and toxicity programs."
As part of its ETAP partnership with Novartis, Singulex has placed its flagship biomarker detection platform, the Erenna system, at Novartis' Basel, Switzerland facility and will be working with Novartis to develop biomarker assays that have the potential to advance Novartis' drug development programs. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.
"Among our goals is the establishment of strong collaborations with pharmaceutical companies that will bring advanced technologies to their translational medicine and biomarker programs," continued Goix. "By opening a facility in Europe, we are bringing our strong immunoassay development skills and Erenna technology closer to European partners. We are actively working to expand our footprint across the globe, and this facility does just that."
Singulex develops and commercializes innovative technology solutions
that enable disease understanding and management for life science
researchers and clinicians. Utilizing proprietary quantitative single
|SOURCE Singulex Inc.|
Copyright©2008 PR Newswire.
All rights reserved